Spelling suggestions: "subject:"high dose date"" "subject:"high dose rate""
1 |
Desenvolvimento de um objeto simulador para investigação de heterogeneidades em braquiterapia de alta taxa de dose / Development of a phantom for investigations with heterogeneties in high-dose-rate brachytherapyMoura, Eduardo Santana de 26 March 2015 (has links)
A braquiterapia de alta taxa de dose é uma das modalidades mais utilizadas em braquiterapia para o tratamento de câncer. Os diversos avanços tecnológicos, bem como a evolução das técnicas de tratamento tornaram a braquiterapia de alta taxa de dose uma das modalidades de estado da arte para o tratamento de alguns cânceres. Parte deste avanço é creditada à melhoria na acurácia e na prescrição de dose absorvida recomendada ao paciente, ao longo dos anos. Este avanço permite que atualmente seja possível realizar os cálculos dosimétricos, por meio de sistemas de planejamento computadorizado, considerando as heterogeneidades dos pacientes, tais como: tecidos e órgãos com composições diferentes da água (meio de referência em radioterapia), contorno do paciente individualizado, introdução de aplicadores, dentre outros. Tais avanços demandam o controle de qualidade destas ferramentas, com objetivo de assegurar que todo o processo de tratamento seja satisfatório e acurado. Até o momento, a comunidade carece de um sistema experimental capaz de avaliar, considerando os níveis de incerteza, se os sistemas de planejamento computadorizados são aptos a considerar a heterogeneidade dos tratamentos. Neste trabalho, apresentamos o desenvolvimento de medidas experimentais em um objeto simulador, com capacidade de mensurar as diferenças introduzidas pela heterogeneidade por meio de três técnicas dosimétricas experimentais: termoluminescência, filmes radiocrômicos e ionométrica. Os resultados experimentais foram comparados com as simulações de Monte Carlo e com um sistema de planejamento computadorizado comercial, apto a realizar correções de heterogeneidade em braquiterapia. Discutimos as principais etapas de desenvolvimento deste objeto simulador, seus resultados experimentais e as comparações com os demais sistemas. As conclusões e as etapas futuras deste projeto também são apresentadas. / High dose rate brachytherapy is one of the most widely used modalities in brachytherapy for cancer treatment The various technological advances and the development of treatment techniques have made high dose rate brachytherapy as one of the state of the art methods for the treatment of some cancers. Part of this progress is credited to the improvement in the accuracy and absorbed dose prescription recommended to patients over the years. This advance currently allows the possibility of performing dosimetric calculations, by means of computerized planning systems, considering the heterogeneity of patients, such as: tissues and organs with different water compositions (reference medium in radiotherapy), individualized patient\'s contour and introduction of applicators, among others. Such advances require quality control of these tools, in order to ensure that the entire treatment process is satisfactory and accurate. Nowadays, the community needs an experimental system capable of evaluating, since the uncertainty levels if the computerized planning systems are able to consider the heterogeneity of treatments. In this project, we present the development of experimental measurements into a phantom, capable of measuring the differences introduced by heterogeneity through three experimental dosimetric techniques: thermoluminescence, radiochromic films and ionometric. The experimental results were compared with the Monte Carlo simulations and a commercial treatment planning system able to perform correction of heterogeneity in brachytherapy. We discuss the main stages of development of this phantom, their experimental results and comparisons with other systems. The conclusions and future steps to complete this project are also presented.
|
2 |
Desenvolvimento de um objeto simulador para investigação de heterogeneidades em braquiterapia de alta taxa de dose / Development of a phantom for investigations with heterogeneties in high-dose-rate brachytherapyEduardo Santana de Moura 26 March 2015 (has links)
A braquiterapia de alta taxa de dose é uma das modalidades mais utilizadas em braquiterapia para o tratamento de câncer. Os diversos avanços tecnológicos, bem como a evolução das técnicas de tratamento tornaram a braquiterapia de alta taxa de dose uma das modalidades de estado da arte para o tratamento de alguns cânceres. Parte deste avanço é creditada à melhoria na acurácia e na prescrição de dose absorvida recomendada ao paciente, ao longo dos anos. Este avanço permite que atualmente seja possível realizar os cálculos dosimétricos, por meio de sistemas de planejamento computadorizado, considerando as heterogeneidades dos pacientes, tais como: tecidos e órgãos com composições diferentes da água (meio de referência em radioterapia), contorno do paciente individualizado, introdução de aplicadores, dentre outros. Tais avanços demandam o controle de qualidade destas ferramentas, com objetivo de assegurar que todo o processo de tratamento seja satisfatório e acurado. Até o momento, a comunidade carece de um sistema experimental capaz de avaliar, considerando os níveis de incerteza, se os sistemas de planejamento computadorizados são aptos a considerar a heterogeneidade dos tratamentos. Neste trabalho, apresentamos o desenvolvimento de medidas experimentais em um objeto simulador, com capacidade de mensurar as diferenças introduzidas pela heterogeneidade por meio de três técnicas dosimétricas experimentais: termoluminescência, filmes radiocrômicos e ionométrica. Os resultados experimentais foram comparados com as simulações de Monte Carlo e com um sistema de planejamento computadorizado comercial, apto a realizar correções de heterogeneidade em braquiterapia. Discutimos as principais etapas de desenvolvimento deste objeto simulador, seus resultados experimentais e as comparações com os demais sistemas. As conclusões e as etapas futuras deste projeto também são apresentadas. / High dose rate brachytherapy is one of the most widely used modalities in brachytherapy for cancer treatment The various technological advances and the development of treatment techniques have made high dose rate brachytherapy as one of the state of the art methods for the treatment of some cancers. Part of this progress is credited to the improvement in the accuracy and absorbed dose prescription recommended to patients over the years. This advance currently allows the possibility of performing dosimetric calculations, by means of computerized planning systems, considering the heterogeneity of patients, such as: tissues and organs with different water compositions (reference medium in radiotherapy), individualized patient\'s contour and introduction of applicators, among others. Such advances require quality control of these tools, in order to ensure that the entire treatment process is satisfactory and accurate. Nowadays, the community needs an experimental system capable of evaluating, since the uncertainty levels if the computerized planning systems are able to consider the heterogeneity of treatments. In this project, we present the development of experimental measurements into a phantom, capable of measuring the differences introduced by heterogeneity through three experimental dosimetric techniques: thermoluminescence, radiochromic films and ionometric. The experimental results were compared with the Monte Carlo simulations and a commercial treatment planning system able to perform correction of heterogeneity in brachytherapy. We discuss the main stages of development of this phantom, their experimental results and comparisons with other systems. The conclusions and future steps to complete this project are also presented.
|
3 |
ROLE OF CHEMOTHERAPY IN IMPROVING DYSPHAGIA FREE SURVIVAL IN PATIENTS WITH ADVANCED ESOPHAGEAL CANCER TREATED WITH HIGH DOSE RATE BRACHYTHERAPYTimotin, Emilia Olimpia 06 February 2015 (has links)
BACKGROUND
High dose rate Intraluminal Brachytherapy (HDRILBT) is one of the most used palliative treatment options for advanced esophageal cancer. The present study evaluates the role of additional chemotherapy in improving dysphagia free survival (DFS) and overall survival (OS) in patients with inoperable advanced esophageal cancer treated with brachytherapy.
MATERIAL and METHODS
132 patients with advanced metastatic esophageal cancer with total or near total dysphagia were given HDRILBT to a dose of 18 Gray (Gy) in 3 fractions on alternate days. Intraluminal brachytherapy alone was performed on 98 patients. 34 patients received Epirubicin, 5-Fluorouracil, and Cisplatin (ECF) chemotherapy regimen after HDRILBT. The mean age of the whole group was 65 years (HDRILBT-71.41, HDRILBT+ECF-59.98; p<0.0001). Male: Female was 101:31 (HDRILBT 72:26; HDRILBT +ECF 29:5; p>0.05). The location incidence was GEJ: Lower Esophagus: Mid Esophagus: Cervical Esophagus 24:81:17:5 respectively; for the whole group HDRILBT- 17:57:16:4; HDRILBT+ECF-7:24:1:1; p>0.05. 78 patients presented with co-morbidities (cardiac) (HDRILBT- 59; HDRILBT+ECF- 19; p>0.05). 74 patients presented with distant metastasis (54 with HDRILBT and 20 with HDRILBT+ECF; p>0.05). The ECOG scores were as follows 0:1:2:3:4 15:52:51:12:2 (HDRILBT- 10:35:41:10:2; HDRILBT+ECF- 5:17:10:2:0; p=0.0014). All patients completed 3 fractions of HDRILBT. 34 patients received additional chemotherapy with ECF regimen. Selection of patients was done by the medical oncologist. Statistical analysis of data was done using the SAS statistical analysis software system. Univariate and multivariate analysis was done using the log rang test.
RESULTS
Patients who received additional ECF were younger (p< 0.001) and with a better performance status than those who received HDRILBT alone (p=0.0014). Mean DFS was higher for patients who had further chemotherapy treatment (232 days) vs. patients who had HDRILBT only (155 days) (p>0.05). The mean OS for HDRILBT + ECF was 266 days (p = 0.0010) compare with HDRILBT alone which was 155 days, when the effect of 10 prognostic factors was analyzed for DFS and OS. Only additional ECF after brachytherapy impacted on DFS while age (p<0.001) and performance status (p=0.0014) impacted on overall survival on univariate analysis. On multivariate analysis tumor length and nodal presentation (p<0.000) impacted on OS. The incidence of stricture and fistulae were similar. Chemotherapy related side effects: gastrointestinal tract (25 patients), neurotoxicities (2) and nephrotoxicities (2) were seen as a result of 5-FU and Cisplatin respectively. 18 patients completed at least 3 cycles of ECF.
CONCLUSION
Additional chemotherapy with ECF after HDRILBT improves the DFS and OS in selected patients with advanced esophageal cancer. These patients tend to be younger with better performance status, small tumor length and nodal metastasis. The incidence of complications is similar with more than 50% patients completing at least 3 cycles of chemotherapy. / Thesis / Master of Science (MSc)
|
4 |
Intrakavitäre High-Dose-Rate-Brachytherapie zur Behandlung von Nasentumoren beim HundKrastel, Dorothee 24 June 2010 (has links) (PDF)
Für die Therapie maligner intranasaler Neoplasien beim Hund existieren nur mäßig be-friedigende Behandlungsstrategien. Als Therapiemodalität der Wahl wird die Radiothe-rapie angesehen, die gegenwärtig v.a. in Form einer perkutanen Bestrahlung (Telethe-rapie) mit aufwendigen, bis zu 20 Fraktionen umfassenden Protokollen kurativer Intenti-on angewendet wird. Die erreichbaren Überlebenszeiten sind meist limitiert durch das Auftreten eines Rezidivs des Nasentumors innerhalb des Bestrahlungsfeldes, sodass eine Erhöhung der applizierten Gesamtdosis nötig erscheint. Dies ist jedoch im Rahmen einer Teletherapie aufgrund nicht vertretbarer akuter Nebenwirkungen nicht möglich. Alternativ steht die Brachytherapie zur Verfügung, die aufgrund ihrer physikalischen Charakteristika zur besseren Schonung des umliegenden Normalgewebes beiträgt. Ge-genwärtig existieren keine anderen Untersuchungen zur Anwendung der fraktionierten High-Dose-Rate-Brachytherapie bei Nasentumoren des Hundes. Ziel dieser Studie war es daher, die Durchführbarkeit dieser Therapiemodalität beim Hund erstmals zu unter-suchen und die akuten und chronischen Nebenwirkungen sowie die erzielbare progres-sionsfreie Zeit und die Überlebenszeit zu dokumentieren.
Im Zeitraum von 2001 bis 2007 gingen 18 Hunde in die Studie ein. Das diagnostische Vorgehen beinhaltete neben einer klinischen Untersuchung und der Röntgenuntersu-chung von Nase und Thorax auch die kernspintomographische Beurteilung der Nasen-höhlen und eine nachfolgende Rhinoskopie inklusive Biopsie. Die Therapie bestand aus zwei wöchentlichen Fraktionen, bei denen in Vollnarkose über einen in der Nasenhöhle applizierten Katheter mithilfe des Radioisotops 192Iridium jeweils 5 Gy appliziert wurden. Die damit über vier Wochen erreichte Gesamtdosis lag bei 40 Gy, und entsprach damit der biologischen Effizienz einer perkutan applizierten konventionell fraktionierten Ge-samtdosis von circa 60 Gy. Im Anschluss an die Therapie wurden die Hunde monatlich klinisch untersucht und die auftretenden Nebenwirkungen anhand des Radiation Morbi-dity Scores der VRTOG beschrieben. Es wurden außerdem weiterführende Untersu-chungen in Form von MRT, Rhinoskopie und Biopsie durchgeführt. Die aufgetretenen Nebenwirkungen waren mit denen in der Literatur nach Teletherapie beschriebenen vergleichbar, beziehungsweise fielen im Bereich von Augen und Maulschleimhaut ge-ringer aus. Nebenwirkungen im Bereich der Haut traten in Form von Alopezie, Hyper-pigmentation oder Leukotrichie auf. Im Bereich der Nasenschleimhaut zeigten fast alle Hunde eine leichte chronische Rhinitis. Als problematische Nebenwirkungen traten bei drei Patienten Osteoradionekrosen auf, die einer aufwendigeren chirurgischen Versor-gung bedurften. Die mediane progressionsfreie Zeit lag bei 13 Monaten, die mediane Überlebenszeit bei 17 Monaten. Die Adenokarzinome wiesen die längste Überlebens-zeit auf, dies war jedoch aufgrund der insgesamt kleinen Patientenzahl nicht signifikant. Ein Zusammenhang zwischen dem Tumorstadium und der progessionsfreien Zeit oder Überlebenszeit bestand nicht.
Bei dem beschriebenen Protokoll handelt es sich um eine unter klinischen Bedingungen praktikable Therapieform, die mit ihren insgesamt acht Fraktionen für Besitzer und Tier wesentlich weniger belastend ist als teletherapeutische kurative Protokolle mit 12-20 Fraktionen. Gleichzeitig gelingt es, eine Gesamtdosis von verhältnismäßig hoher biolo-gischer Effizienz zu applizieren, ohne jedoch stärkere Nebenwirkungen in Kauf nehmen zu müssen. Im Bereich von Auge und Maulschleimhaut sind die Nebenwirkungen sogar geringer. Bei einem kleinen Teil der Patienten treten jedoch auch hier, ebenso wie nach teletherapeutischen Protokollen, problematische chronische Nebenwirkungen auf, die die Lebensqualität der betroffenen Tiere beeinträchtigen und die einer aufwendigeren Therapie zwingend bedürfen. Die mit diesem Protokoll erreichten Remissions- und Ü-berlebenszeiten sind mit denen aus der Literatur vergleichbar bis tendenziell besser. Aufgrund der oben genannten Vorteile erscheint die vorgestellte Therapie daher als Al-ternative zu Teletherapie bei der Behandlung kaniner Nasentumoren durchaus geeig-net. Weitere Studien mit größeren Patientenzahlen unter Einbeziehung einer anders therapierten Kontrollgruppe sind jedoch notwendig
|
5 |
Intrakavitäre High-Dose-Rate-Brachytherapie zur Behandlung von Nasentumoren beim HundKrastel, Dorothee 06 April 2010 (has links)
Für die Therapie maligner intranasaler Neoplasien beim Hund existieren nur mäßig be-friedigende Behandlungsstrategien. Als Therapiemodalität der Wahl wird die Radiothe-rapie angesehen, die gegenwärtig v.a. in Form einer perkutanen Bestrahlung (Telethe-rapie) mit aufwendigen, bis zu 20 Fraktionen umfassenden Protokollen kurativer Intenti-on angewendet wird. Die erreichbaren Überlebenszeiten sind meist limitiert durch das Auftreten eines Rezidivs des Nasentumors innerhalb des Bestrahlungsfeldes, sodass eine Erhöhung der applizierten Gesamtdosis nötig erscheint. Dies ist jedoch im Rahmen einer Teletherapie aufgrund nicht vertretbarer akuter Nebenwirkungen nicht möglich. Alternativ steht die Brachytherapie zur Verfügung, die aufgrund ihrer physikalischen Charakteristika zur besseren Schonung des umliegenden Normalgewebes beiträgt. Ge-genwärtig existieren keine anderen Untersuchungen zur Anwendung der fraktionierten High-Dose-Rate-Brachytherapie bei Nasentumoren des Hundes. Ziel dieser Studie war es daher, die Durchführbarkeit dieser Therapiemodalität beim Hund erstmals zu unter-suchen und die akuten und chronischen Nebenwirkungen sowie die erzielbare progres-sionsfreie Zeit und die Überlebenszeit zu dokumentieren.
Im Zeitraum von 2001 bis 2007 gingen 18 Hunde in die Studie ein. Das diagnostische Vorgehen beinhaltete neben einer klinischen Untersuchung und der Röntgenuntersu-chung von Nase und Thorax auch die kernspintomographische Beurteilung der Nasen-höhlen und eine nachfolgende Rhinoskopie inklusive Biopsie. Die Therapie bestand aus zwei wöchentlichen Fraktionen, bei denen in Vollnarkose über einen in der Nasenhöhle applizierten Katheter mithilfe des Radioisotops 192Iridium jeweils 5 Gy appliziert wurden. Die damit über vier Wochen erreichte Gesamtdosis lag bei 40 Gy, und entsprach damit der biologischen Effizienz einer perkutan applizierten konventionell fraktionierten Ge-samtdosis von circa 60 Gy. Im Anschluss an die Therapie wurden die Hunde monatlich klinisch untersucht und die auftretenden Nebenwirkungen anhand des Radiation Morbi-dity Scores der VRTOG beschrieben. Es wurden außerdem weiterführende Untersu-chungen in Form von MRT, Rhinoskopie und Biopsie durchgeführt. Die aufgetretenen Nebenwirkungen waren mit denen in der Literatur nach Teletherapie beschriebenen vergleichbar, beziehungsweise fielen im Bereich von Augen und Maulschleimhaut ge-ringer aus. Nebenwirkungen im Bereich der Haut traten in Form von Alopezie, Hyper-pigmentation oder Leukotrichie auf. Im Bereich der Nasenschleimhaut zeigten fast alle Hunde eine leichte chronische Rhinitis. Als problematische Nebenwirkungen traten bei drei Patienten Osteoradionekrosen auf, die einer aufwendigeren chirurgischen Versor-gung bedurften. Die mediane progressionsfreie Zeit lag bei 13 Monaten, die mediane Überlebenszeit bei 17 Monaten. Die Adenokarzinome wiesen die längste Überlebens-zeit auf, dies war jedoch aufgrund der insgesamt kleinen Patientenzahl nicht signifikant. Ein Zusammenhang zwischen dem Tumorstadium und der progessionsfreien Zeit oder Überlebenszeit bestand nicht.
Bei dem beschriebenen Protokoll handelt es sich um eine unter klinischen Bedingungen praktikable Therapieform, die mit ihren insgesamt acht Fraktionen für Besitzer und Tier wesentlich weniger belastend ist als teletherapeutische kurative Protokolle mit 12-20 Fraktionen. Gleichzeitig gelingt es, eine Gesamtdosis von verhältnismäßig hoher biolo-gischer Effizienz zu applizieren, ohne jedoch stärkere Nebenwirkungen in Kauf nehmen zu müssen. Im Bereich von Auge und Maulschleimhaut sind die Nebenwirkungen sogar geringer. Bei einem kleinen Teil der Patienten treten jedoch auch hier, ebenso wie nach teletherapeutischen Protokollen, problematische chronische Nebenwirkungen auf, die die Lebensqualität der betroffenen Tiere beeinträchtigen und die einer aufwendigeren Therapie zwingend bedürfen. Die mit diesem Protokoll erreichten Remissions- und Ü-berlebenszeiten sind mit denen aus der Literatur vergleichbar bis tendenziell besser. Aufgrund der oben genannten Vorteile erscheint die vorgestellte Therapie daher als Al-ternative zu Teletherapie bei der Behandlung kaniner Nasentumoren durchaus geeig-net. Weitere Studien mit größeren Patientenzahlen unter Einbeziehung einer anders therapierten Kontrollgruppe sind jedoch notwendig
|
6 |
High dose-rate brachytherapy in the radical treatment of cervical cancer. An analysis of dose effectiveness and incidence of late radiation complicationsLong, D., Friedrich-Nel, H., Goedhals, L., Joubert, G. January 2011 (has links)
Published Article / Worldwide, uterine cervical cancer is one of the most frequently occurring cancers in women, with more than 80% of these cases occurring in developing countries. The South African screening policy and screening program, implemented in 2001, attempt to reduce this incidence of cervical cancer in South Africa. It is essential to treat these women with the best modalities available. This retrospective study focused specifically on the curative potential of radiotherapy administered to patients at the Oncology Department, Bloemfontein, since a new modality of high dose-rate intracavitary brachytherapy was implemented in 1994. Late radiation complications were also investigated.
|
7 |
Digital Holographic Interferometry for Radiation DosimetryCavan, Alicia Emily January 2015 (has links)
A novel optical calorimetry approach is proposed for the dosimetry of therapeutic radiation,
based on the optical technique of Digital Holographic Interferometry (DHI). This detector
determines the radiation absorbed dose to water by measurement of the refractive index variations
arising from radiation induced temperature increases. The output consists of a time
series of high resolution, two dimensional images of the spatial distribution of the projected
dose map across the water sample. This absorbed dose to water is measured directly, independently
of radiation type, dose rate and energy, and without perturbation of the beam.
These are key features which make DHI a promising technique for radiation dosimetry.
A prototype DHI detector was developed, with the aim of providing proof-of-principle of the
approach. The detector consists of an optical laser interferometer based on a lensless Fourier
transform digital holography (LFTDH) system, and the associated mathematical reconstruction
of the absorbed dose. The conceptual basis was introduced, and a full framework was
established for the measurement and analysis of the results. Methods were developed for
mathematical correction of the distortions introduced by heat di usion within the system.
Pilot studies of the dosimetry of a high dose rate Ir-192 brachytherapy source and a small
eld proton beam were conducted in order to investigate the dosimetric potential of the technique.
Results were validated against independent models of the expected radiation dose
distributions.
Initial measurements of absorbed dose demonstrated the ability of the DHI detector to resolve
the minuscule temperature changes produced by radiation in water to within experimental
uncertainty. Spatial resolution of approximately 0.03 mm/pixel was achieved, and the dose
distribution around the brachytherapy source was accurately measured for short irradiation
times, to within the experimental uncertainty. The experimental noise for the prototype
detector was relatively large and combined with the occurrence of heat di usion, means that
the method is predominantly suitable for high dose rate applications.
The initial proof-of-principle results con rm that DHI dosimetry is a promising technique,
with a range of potential bene ts. Further development of the technique is warranted, to
improve on the limitations of the current prototype. A comprehensive analysis of the system
was conducted to determine key requirements for future development of the DHI detector
to be a useful contribution to the dosimetric toolbox of a range of current and emerging applications.
The sources of measurement uncertainty are considered, and methods suggested
to mitigate these. Improvement of the signal-to-noise ratio, and further development of the
heat transport corrections for high dose gradient regions are key areas of focus highlighted
for future development.
|
8 |
Improving high dose rate and pulsed dose rate prostate brachytherapy - alternative prostate definition and treatment delivery verification methodsHowie, Andrew Gordon, howie.andrew@gmail.com January 2009 (has links)
Brachytherapy is a form of radiotherapy in which radioactive sources are placed at short distances from, or even inside the target volume. The use of high dose rate brachytherapy is a widely accepted and clinically proven treatment for some stages of prostate cancer. The aim of this project was to investigate potential improvements on two of the most important aspects of high dose rate (HDR) and pulsed dose rate (PDR) prostate brachytherapy - prostate definition and treatment delivery verification. The use of magnetic resonance (MR) imaging in addition to the conventional computed tomography (CT) imaging methods currently used routinely for brachytherapy planning may provide some benefit in accurately defining the prostate and surrounding critical structures. The methods used in this project involved analysis of data sets provided by two Radiation Oncologists. The results presented showed inter-observer and intra-observer variations in the size and shape of the prostate, as well as analysis of the dosimetric differences that may be reported due to the differences in prostate size and shape. The results also included analysis of critical structure dosimetry - dose to the surrounding radio-sensitive rectum and urethra. In summary, the results showed that the prostate was defined to be smaller using MR imaging than CT, however the consistency between Oncologists was not significantly improved using MR imaging. MR imaging may be useful in reducing the dose to normal tissue surrounding the prostate and in obtaining better coverage of the smaller target volume, without compromising the critical structures. The use of LiF:Mg,Ti thermoluminescent dosimeters (TLDs) is a potential avenue for in vivo dose verification of an HDR or PDR prostate brachytherapy treatment plan. This project included a phantom study of these TLDs with the aim to determine their feasibility for clinical use. Cylindrical TLD rods (6 mm length x 1 mm diameter) were used, as these fit inside the brachytherapy needles implanted into the prostate, and therefore had potential to be used clinically to verify the dose delivered in the prostate. This study was extended to include determination of a correction factor to allow an independent radiation source (6 MV photon beam from a linear accelerator) to be used to obtain control readings for this relative dosimetric method. The results showed these TLDs to be a promising in vivo dosimeter for prostate brachytherapy with potential errors in the order of 4%. Their potential lies in the fact that they could detect and flag significant calculation errors in treatment plans, and they utilise equipment used routinely for external beam radiotherapy dosimetry in many treatment facilities, reducing the cost of implementing such a procedure.
|
9 |
Mise en place et utilisation des faisceaux FFF en radiothérapie : radiobiologie, caractérisation physique, contrôles qualité, modélisation et planification de traitement / Setup and use of FFF beams in radiation therapy : radiobiology, physical characterization, quality controls, modelling and treatment planningValdenaire, Simon 10 February 2017 (has links)
Les faisceaux de photons produits par les accélérateurs d'électrons linéaires médicaux sont plats, grâce à un cône égalisateur. Les technologies ont évolué et la présence d'un cône n'est plus indispensable. On parle alors de faisceaux FFF (flattening filter free). Les faisceaux FFF présentent des débits de dose plus élevés, des profils de dose hétérogènes, des spectres énergétiques différents et une diminution de la dose hors-champ. Cette thèse a eu pour but d'étudier les caractéristiques des faisceaux FFF, ainsi que l'impact de leur utilisation thérapeutique. Plusieurs thématiques ont été. Des expériences d'irradiation in vitro ont tout d'abord permis de s'assurer que les débits de dose FFF n'ont pas d'impact radiobiologique sur la réponse des cellules irradiées. Une large revue de la littérature a permis de corroborer ces résultats. Afin de maitriser les caractéristiques physiques des faisceaux FFF, des mesures ont été faites avec différents détecteurs. Les effets du spectre et du débit de dose sur la calibration en dose ont aussi été étudiés. Les faisceaux FFF ont été modélisés dans deux TPS. Les modèles ont été comparés entre les deux types de faisceaux et entre les deux TPS. La mise en place des traitements stéréotaxiques a aussi été l'occasion d'appréhender la dosimétrie des petits faisceaux. Nous avons étudié des cas VMAT de cancer de la prostate et des cas de stéréotaxies 3D de tumeurs pulmonaires. La comparaison donne un avantage aux faisceaux FFF. La maitrise de la physique et de la biologie des haut débits a permis de débuter les traitements FFF à l'IPC. Des études comparatives nous permettent aujourd'hui d'adapter leur utilisation au cas par cas. / In medical linear electron accelerators, photon beams profiles are homogenised using flattening filters. Technologies have evolved and the presence of this filter is no longer necessary. Flattening filter free (FFF) beams exhibit higher dose rates, heterogeneous dose profiles, modified energy spectra and lower out-of-field dose. This PhD aimed at studying the characteristics of unflattened beams, as well as their impact in clinical utilization. Several subjects were thoroughly investigated: radiobiology, dosimetry, quality controls, modelling and treatment planning. In vitro experiments ensured that the high dose-rate of FFF beams had not a radiobiological impact. A wide review of the literature was conducted to corroborate these results. In order to understand thoroughly the characteristics of FFF beams, measurements were conducted using several detectors. The effect of the spectra and dose rates of unflattened beams on dose calibration were also studied. FFF beams were modeled in two TPSs. The methods, results and model parameters have been compared between the available beam qualities as well as between both TPSs. Furthermore, the implementation of stereotactic treatments technique was the occasion to investigate small beam dosimetry. Prostate cancer cases treated with VMAT and pulmonary tumors treated with stereotactic 3D beams were also studied. The comparison of dose distributions and treatment metrics give advantage to FFF beams. Mastering physical and biological aspects of flattening filter free beams allowed the IPC to start FFF treatments. Comparative studies have since resulted in a deeper understanding on the pertinent use of these beams.
|
10 |
Predicting toxicity caused by high-dose-ratebrachytherapy boost for prostate cancerEstefan, Dalia January 2019 (has links)
Introduction Treating localized prostate cancer with combination radiotherapy consisting ofexternal beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) has beenproven to result in better disease outcome than EBRT only. There is, however, a decreasingtrend in utilization of combination therapy, partially due to concerns for elevated toxicityrisks. Aim To determine which parameters correlate to acute and late (≤ 6 months) urinary toxicity(AUT and LUT) and acute and late rectal toxicity (ART and LRT), and thereafter createpredictive models for rectal toxicity. Methods Data on toxicity rates and 32 patient, tumor and treatment parameters were collectedfrom 359 patients treated between 2008 and 2018 with EBRT (42 Gy in 14 fractions) andHDR-BT (14.5 Gy in 1 fraction) for localized prostate cancer at Örebro University Hospital.Bivariate analyses were conducted on all parameters and the outcome variables AUT, LUT,ART and LRT grade ≥ 1, graded according to the RTOG-criteria. Parameters correlating toART and LRT in this and previous studies were included in multivariate logistic regressionanalyses for creation of predictive models. Results Most toxicities, 86%, were of grade 0 or 1, only 9% of patients had grade 2 – 3toxicity. Only 2 – 4 parameters correlated to the respective toxicities in bivariate analyses.Logistic regressions generated no significant predictors of ART or LRT. Therefore, nopredictive models were obtained. Conclusion None of the included parameters have enough discriminative abilities regardingrectal toxicity. Predictive models can most probably be obtained by including otherparameters and more patients.
|
Page generated in 0.0506 seconds